Literature DB >> 6727656

Does acute endogenous hyperprolactinemia affect intravenous glucose tolerance in humans?

S Röjdmark, K Lamminpää.   

Abstract

To investigate whether acute endogenous hyperprolactinemia (h-PRL) influences glucose tolerance in humans, two intravenous glucose tolerance tests were performed in healthy subjects and in patients with untreated type 2 diabetes. One of the tests was carried out during h-PRL induced by oral priming with 10 mg metoclopramide (MET). The other was performed during normoprolactinemia (n-PRL) prevailing after oral priming with placebo. The glucose disappearance rates (Kg) were compared in the n-PRL and h-PRL states. In eight healthy subjects with high Kg values (greater than or equal to 1.2) during n-PRL, the glucose tolerance decreased during MET-induced h-PRL. This was reflected by a Kg fall from 2.0 +/- 0.4 during n-PRL to 1.3 +/- 0.3 during h-PRL (P less than 0.01). It is unlikely that this Kg decline could have been caused by prolactin-induced changes in serum levels of insulin, cortisol, or growth hormone (GH), since these hormones showed glucose-elicited response patterns that were similar in the n-PRL and h-PRL states. It is also improbable that MET per se could have caused Kg to fall, inasmuch as MET left Kg unaffected when oral pretreatment with bromocriptine prevented MET from inducing h-PRL in an additional five healthy subjects with high Kg values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727656     DOI: 10.1016/0026-0495(84)90013-1

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  2 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  In vivo insulin antagonism but evanescent in vitro tissue effect in rats with growth hormone-secreting tumors.

Authors:  M B Davidson; D C Shen; N Venkatesan; G Sladen
Journal:  J Endocrinol Invest       Date:  1987-12       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.